Pay in 4 interest-free payments of $5.82 Learn more
Ships within 48 hours · Estimated delivery Oct 28 - Nov 2
Development of a screening system for inteins active in protein splicing based on intein insertion into the LacZ-peptide
Non-target lesion progression was found in 10.19% (11/108) patient of the GLP-1RA group and 22.12% (23/104) in the control group ( P = 0.037)
In 2024, Novo Nordisk reported a total revenue of $40.66 billion, of which $20.88 billion was attributed to its GLP-1 drugs, which accounted for 51.4% of total revenues
Liu X, Li K, Shi L, et al
US$ 26.09
US$ 23.75
US$ 27.60
US$ 23.61
US$ 25.92
US$ 25.12
US$ 25.81
US$ 27.68
